Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.

Junning Cao,Pin Zhang,Paul de Souza,Bo Gao,Mark Voskoboynik,Dongmei Ji,Weina Shen,Sheng Yang,Yinglei Zhou,Rong Zhang,Jason D. Lickliter,Siao-Nge Hoon,D. Palmieri,Suixiong Cai,Ye Edward Tian,Ning Ma,Cong Xu,Stone Yang,Shuaishuai Zhang,Binghe Xu

Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.

2019

3059Background: Poly (ADP-ribose) polymerase (PARP) enzymes play critical roles in DNA damage detection and repair. IMP4297 is a novel, potent PARP1/2 inhibitor (IC50 6.27nM/1.57nM) and has demonst...

Keywords:

PARP inhibitor
Cohort
Pathology
Oncology
Internal medicine
Medicine
Poly ADP ribose polymerase
DNA damage
Enzyme
Cancer research
PARP1
IC50
Polymerase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations